Trinity Capital Inc. announced a $30 million growth‑capital commitment to Iantrek, a medical‑technology company that develops bio‑interventional ophthalmic surgery solutions, on April 28, 2026. The financing is intended to support Iantrek’s commercial expansion, advance development and regulatory activities for its pipeline products, and scale manufacturing and distribution capabilities.
Iantrek, which focuses on restoring natural fluid outflow pathways in the eye, raised $42 million in a Series C round in August 2025. The company’s lead commercial technology, AlloFlo Uveo, is a bio‑tissue implant designed to enhance uveoscleral outflow for chronic eye diseases such as glaucoma.
Trinity Capital’s recent performance underscores its active investment strategy. In Q4 2025 the firm reported earnings per share of $0.52, beating estimates of $0.51, and in Q1 2025 it generated net investment income of $32.4 million, or $0.52 per share. In the first quarter of 2026, Trinity Capital funded $306 million in new investments and announced $395 million in new commitments, reflecting a consistent deployment pace in the life‑sciences sector.
Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital, said, “We believe Iantrek’s innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology. We are pleased to support their team as they enter this next phase of rapid growth.” Adam Szaronos, CEO of Iantrek, added, “This financing is a strategic step to keep pace with growing physician demand for our platform. It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology, and advance the next wave of bio‑interventional innovation.”
The transaction aligns with Trinity Capital’s broader focus on growth capital for life‑science companies. The firm has recently committed $50 million each to Cala Health and Sage Health, and its Q1 2026 activity demonstrates a steady pipeline of deals. By providing Iantrek with additional capital, Trinity Capital is reinforcing its position as a key partner for companies advancing novel medical technologies.
The $30 million commitment will enable Iantrek to accelerate its commercial rollout, support regulatory submissions for pipeline products, and expand manufacturing and distribution infrastructure. No market reaction data were identified in the fact‑check report, but the deal represents a significant capital infusion for a company poised for rapid growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.